| Stereochemistry | ACHIRAL |
| Molecular Formula | C17H19N3O4S |
| Molecular Weight | 361.415 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
COC1=CC2=C(NC(=N2)S(=O)(=O)CC3=NC=C(C)C(OC)=C3C)C=C1
InChI
InChIKey=IXEQEYRTSRFZEO-UHFFFAOYSA-N
InChI=1S/C17H19N3O4S/c1-10-8-18-15(11(2)16(10)24-4)9-25(21,22)17-19-13-6-5-12(23-3)7-14(13)20-17/h5-8H,9H2,1-4H3,(H,19,20)
| Molecular Formula | C17H19N3O4S |
| Molecular Weight | 361.415 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Omeprazole sulfone is the major metabolite of the omeprazole, gastric proton pump inhibitor. Metabolite is formed by the sulfoxidation of the omeprazole under the action of cytochrome P450 (CYP)3A4. Omeprazole sulfone is found in plasma and shows elimination rate–limited kinetics in vivo. Omeprazole sulfone has been shown to act as a reversible direct-acting and metabolism-dependent inhibitor of CYP2C19.
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
| 5.7 µM [Ki] |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
